Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Anal Cancer Metastatic × atezolizumab × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 67 Colorectal Neoplasms 34 Stomach Neoplasms 15 Carcinoma, Non-Small-Cell Lung 13 Liver Neoplasms 12 Neoplasms 9 Melanoma 9 Carcinoma, Renal Cell 9 Pancreatic Neoplasms 8 Esophageal Neoplasms 8 Breast Neoplasms 8 Ovarian Neoplasms 7 Head and Neck Neoplasms 7 Carcinoma, Transitional Cell 7 Uterine Cervical Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Small Cell Lung Carcinoma 6 Rectal Neoplasms 6 Colonic Neoplasms 6 Cholangiocarcinoma 6 Urinary Bladder Neoplasms 5 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 5 Gastrointestinal Neoplasms 5 Carcinoma, Merkel Cell 5 Biliary Tract Neoplasms 4 Sarcoma 3 Prostatic Neoplasms 3 Lung Neoplasms 3 Turcot syndrome 2

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07280377 2025-12-12

GOBLET

Oncolytics Biotech

Phase 1/2 Recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡